ClinicalTrials.gg
WithdrawnNCT01393145Updated Feb 15, 2017

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

A Phase 3 interventional study of Combination Fluticasone /Formoterol 12/250 μg and Seretide Diskus (salmeterol/fluticasone) 50/250 μg in Chronic Obstructive Pulmonary Disease and COPD, sponsored by Ache Laboratorios Farmaceuticos S.A.. Withdrawn. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-02-15.

Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

A study multicenter, phase III, randomized, open label study to evaluate the efficacy and safety of a fixed-dose combination of formoterol/fluticasone and salmeterol/fluticasone in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) that will enroll 336 subjects aged ≥ 40 years, smokers or former smokers, diagnosed with chronic obstructive pulmonary disease, classified as moderate chronic obstructive pulmonary disease or severe according to GOLD spirometric classification. The subjects will be allocated in 2 parallel groups and will receive the medicines of study, according of the randomization during a 24-week.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • COPD

Keywords

  • Chronic obstructive pulmonary disease (COPD)
  • salmeterol
  • fluticasone
  • formoterol
  • FEV1
  • Moderate-to-severe
03

In context

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Ache Laboratorios Farmaceuticos S.A. is the lead sponsor of 36 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 40 years;
  2. classified as moderate or severe according to GOLD guidelines (Global Initiative for Chronic Obstructive Lung Disease), with post-bronchodilator /FVC \<0.70, and post-bronchodilator FEV1 \<80% and ≥ 30% predicted;
  3. Understanding and capacity to give written consent;
  4. Smoker or ex-smoker of ≥ 10 pack-years [number of pack-years = number of daily cigarettes / 20 x number of years of smoking (eg t10 pack-years is equal to 20 cigarettes / day for 10 years, or 10 cigarettes per day within 20 years)].
  5. Ability to fill out the patient's Diary
  6. Ability to fill out the MRC dyspnea scale and questionnaires CAT and CDLM.

Exclusion criteria

Exclusion Criteria:

  1. Presence of clinically associate morbidities manifested according to the investigator that would interfere in the evaluation, for example: diabetes mellitus, congestive heart failure, coronary heart disease, chronic renal failure, liver failure, arrhythmia, hypothyroidism or hyperthyroidism;
  2. Presence of neuro-psychiatric disorders of any kind;
  3. Presence of mental retardation of any etiology;
  4. Presence of pulmonary malformations, bronchiectasis, cystic fibrosis, bronchopulmonary hemosiderosis, ciliary dyskinesia, alveolitis, , pulmonary vasculitis, sarcoidosis, tuberculosis or other lung diseases that might interfere with study assessments, as the investigator's discretion;
  5. Subjects using therapy, immunomodulatory agents, chemotherapy for allergy or any other immunotherapy;
  6. Subjects using xanthine or acebrophylline;
  7. Use within two months preceding the screening visit (V-2) of: anti-leukotrienes, immunoglobulins (including omalizumab), beta blockers, digitalis, itraconazole, amiodarone, antidepressants, monoamine oxidase inhibitors, tricyclic antidepressants, rifampin, oral and coumarin ;
  8. Current diagnosis of asthma;
  9. Symptomatic coronary insufficiency;
  10. Surgery for lung volume reduction and / or lung transplantation;
  11. Need for long-term oxygen therapy (defined as the need for oxygen therapy ≥ 12 hours / day);
  12. Pregnant or test β-HCG serum positive;
  13. Lactating women;
  14. Subject who uses more than 2 alcohol drinks a day or> 14 drinks a week;
  15. Subject with a history of or ≤ 5 years> 5 years, but without documentation of remission / cure.
  16. Illiterate or individuals who have limitation in understanding the use of devices as well as an inability to understand the questionnaires and diary that will be applied; Exception: subject illiterate, but capable of understanding regarding the use of the device, the questionnaires and diaries of the study and make available for relatives who can fill the diary study.
  17. History of hypersensitivity to study drugs and rescue;
  18. Any other disease or therapy that in the opinion of the investigator would jeopardize the subject or interfere with the objective of the study;
  19. Subject with a history of ineffectiveness of formoterol fumarate, to fluticasone or salmeterol xinafoate;
  20. Subject who participated in another study within 1 (one) year;
  21. Pregnant women or those with positive serum β-HCG;
  22. Radiological change is not compatible with ;
  23. changes, as reported by the investigator;
  24. Any other disease, therapy or laboratory abnormality which in the opinion of the investigator would jeopardize the subject or interfere with the objective of the study;
  25. Use of medications prescribed in the exclusion criteria for visit V -2.
  26. Subjects who had an exacerbation during the standardization that required systemic and / or antibiotics or hospitalization will not be eligible for randomization.
  27. Use of oral corticosteroids, anti-leukotrienes, immunoglobulins (including omalizumab), beta blockers, digitalis, amiodarone, itraconazole, antidepressants, monoamine oxidase inhibitors and tricyclic antidepressants during the period of standardization;
  28. Any other disease or therapy that in the opinion of the investigator would jeopardize the subject or interfere with the objective of the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group 1

    Drug: Combination Fluticasone /Formoterol 12/250 μg

  • Active comparator
    Group 2

    Drug: Seretide Diskus (salmeterol/fluticasone) 50/250 μg

Interventions

  • DrugCombination Fluticasone /Formoterol 12/250 μg

    Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®

  • DrugSeretide Diskus (salmeterol/fluticasone) 50/250 μg

    Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses

06

What researchers measure

Primary outcomes

  1. Changes in pre-bronchodilator forced expiratory volume in first second (FEV1)

    Changes of lung function parameter

    Time frame: Comparative between baseline and week 24

Secondary outcomes

  1. Changes in forced expiratory volume in first second, without bronchodilator

    Changes of lung function parameter

    Time frame: Week 0, 8, 16 and 24

  2. Safety descriptive about occurence of adverse events, evaluation of results of clinical/physical examination and laboratory tests results

    Collection of safety data throughout the whole study period

    Time frame: From baseline to week 24

  3. Changes in COPD Assessment Test (CAT)

    Questionnaire

    Time frame: Week 0, 8, 16 and 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2011
First posted
Jul 13, 2011
Start
Aug 2011
Primary completionEst.
Aug 2012
CompletionEst.
Aug 2012
Last update
Feb 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01393145
Responsible party
Sponsor
First posted
Jul 13, 2011
Start date
Aug 2011
Primary completion
Aug 2012 (estimated)
Completion
Aug 2012 (estimated)
Last update
Feb 15, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion